US 12,213,964 B2
Isoxazoline parasiticide formulations
Bobak Robert Azamian, Newport Coast, CA (US); Douglas Michael Ackermann, Reno, NV (US); Shawn D. Hickok, Aliso Viejo, CA (US); and Joseph G. Vehige, Irvine, CA (US)
Assigned to Tarsus Pharmaceuticals, Inc., Irvine, CA (US)
Filed by Tarsus Pharmaceuticals, Inc., Irvine, CA (US)
Filed on May 30, 2023, as Appl. No. 18/325,910.
Application 18/325,910 is a continuation of application No. 17/099,531, filed on Nov. 16, 2020, abandoned.
Application 17/099,531 is a continuation of application No. 16/221,390, filed on Dec. 14, 2018, granted, now 10,835,517, issued on Nov. 17, 2020.
Claims priority of provisional application 62/746,498, filed on Oct. 16, 2018.
Claims priority of provisional application 62/689,787, filed on Jun. 25, 2018.
Claims priority of provisional application 62/626,612, filed on Feb. 5, 2018.
Claims priority of provisional application 62/615,855, filed on Jan. 10, 2018.
Claims priority of provisional application 62/599,213, filed on Dec. 15, 2017.
Prior Publication US 2023/0301971 A1, Sep. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/422 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/26 (2006.01); A61P 27/02 (2006.01); A61P 33/14 (2006.01)
CPC A61K 31/422 (2013.01) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 47/26 (2013.01); A61P 27/02 (2018.01); A61P 33/14 (2018.01)] 21 Claims
 
1. An ophthalmic composition comprising:
an effective amount of an isoxazoline parasiticide,
wherein the isoxazoline parasiticide is present at between about 0.10% and about 0.50% by weight with respect to the total weight of the composition;
a hydrogenated castor oil;
a polysaccharide thickener;
and glycerin,
wherein the glycerin is present at between about 0.5% and about 4% by weight with respect to the total weight of the composition.